Actavis receives final FDA approval for Zolpidem ER Tablets Actavis, an international generic pharmaceuticals organization, today announced that it has received last approval from the united states Food & Drug Administration to market Zolpidem Tartrate Extended-Release Tablets USP, 12.5 mg CIV.5 mg enables Actavis to offer both strengths to meet up the needs of our customers. .The $120 million project, which began in Summer 2008 is definitely operational with the state opening of the 240 now,000 square feet premises prepared for May 2011. With over 20 years experience in clinical supply management ( Almac is recognised seeing that a strategic partner in the clinical source process by pharma and biotech businesses around the world. These recent investments are a indication of their commitment to offer market driven solutions to their customers.
88 % of children who drown are beneath the supervision of someone else New research revealed today by the National SAFE KIDS Marketing campaign and Johnson & Johnson shows that 88 % of children who drowned were beneath the supervision of another person, usually a family member.